Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medifast (MED) Gains from Sales and Divestitures (2016 - 2021)

Medifast (MED) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $26000.0 as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Gains from Sales and Divestitures fell 13.33% year-over-year to $26000.0, compared with a TTM value of $26000.0 through Sep 2021, down 13.33%, and an annual FY2020 reading of $32000.0, down 88.29% over the prior year.
  • Gains from Sales and Divestitures was $26000.0 for Q3 2021 at Medifast, up from $25000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $273300.0 in Q4 2019 and bottomed at $14000.0 in Q1 2021.
  • Average Gains from Sales and Divestitures over 5 years is $61436.6, with a median of $32000.0 recorded in 2019.
  • The sharpest move saw Gains from Sales and Divestitures surged 200.33% in 2019, then plummeted 88.29% in 2020.
  • Year by year, Gains from Sales and Divestitures stood at $120000.0 in 2017, then decreased by 24.17% to $91000.0 in 2018, then soared by 200.33% to $273300.0 in 2019, then tumbled by 88.29% to $32000.0 in 2020, then decreased by 18.75% to $26000.0 in 2021.
  • Business Quant data shows Gains from Sales and Divestitures for MED at $26000.0 in Q3 2021, $25000.0 in Q2 2021, and $14000.0 in Q1 2021.